Reference
1. Ito Y, Miyauchi A, Nakamura Y, Miya A, Kobayashi K, Kakudo K. Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with Member Institutes of The Japanese Society of Thyroid Surgery.Am J Clin Pathol. 2007;127(2):230-236.
2. Gao R, Jia X, Ji T, Feng J, Yang A, Zhang G. Management and Prognostic Factors for Thyroid Carcinoma Showing Thymus-Like Elements (CASTLE): A Case Series Study. Front Oncol. 2018;8:477.
3. Lorenz L, von Rappard J, Arnold W, et al. Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid. Front Oncol.2019;9:734.
4. Tahara I, Oishi N, Mochizuki K, et al. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas. Endocr Pathol. 2020;31(3):274-282.
5. Tsujikawa T, Kumar S, Borkar RN, et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Rep. 2017;19(1):203-217.